Appointment of Independent Director to become effective upon approval by and listing of common stock on a National Exchange

Boca Raton, FL, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) ("Curative Biotech" or the "Company"), a development-stage biomedical company focused on novel treatments for degenerative eye diseases today announced its nomination to its Board of Directors of Dr. Jeffrey Liebmann. Dr. Liebmann is expected to join its Board of Directors as an independent director upon approval by and listing of the Company's common stock on a National Exchange. In addition to other Board duties Dr. Liebmann would be expected to chair the newly created Clinical Development Committee of the Board.

About Dr. Jeffrey Liebmann

Dr. Jeffrey M. Liebmann graduated from Boston University School of Medicine, completed his ophthalmology residency at the State University of New York/Downstate Medical Center, and his glaucoma fellowship at the New York Eye and Ear Infirmary. Dr. Liebmann serves as Shirlee and Bernard Brown Professor, Vice-Chair, and Director of the Glaucoma Division of the Department Ophthalmology at Columbia University Irving Medical Center. He is a fellow of the American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology and American College of Surgeons. Dr. Liebmann serves as a member of the World Glaucoma Association Council, Board of Directors of The Glaucoma Foundation and Secretary-Treasurer of the New York Glaucoma Society. Dr. Liebmann is a past-President of the World Glaucoma Association, American Glaucoma Society, and the New York Society for Clinical Ophthalmology, Emeritus Editor-in Chief of Journal of Glaucoma and was co-founder of the New York Glaucoma Research Institute, the American Glaucoma Society Foundation and ASCRS Glaucoma Day.

In addition to maintaining a busy tertiary-care referral practice in New York City, Dr. Liebmann is Principal Investigator for the NIH African Descent and Glaucoma Evaluation Study (ADAGES) and Ocular Hypertension Treatment Study (OHTS III) at Columbia University and is the author and/or co-author of more than 1000 medical and scientific papers, book chapters, and abstracts. He has lectured widely in the United States and abroad on glaucoma diagnosis and management. His current main areas of research interest include the causes of glaucoma, glaucoma progression, glaucoma surgery, ocular imaging, and neuroprotection.

"We could not be more pleased" said Paul Michaels, Executive Chairman of Curative and CEO of Curative's wholly owned Japanese subsidiary Curative Biotech Japan K.K. "Dr. Liebmann is recognized as a world leader in his field and his insights and guidance will prove invaluable as Curative moves into clinical development of its Metformin-based eye drops to treat degenerative eye diseases."

"I look forward to working with the leadership and scientists at Curative Biotechnologies to develop and advance new products to preserve vision" said Dr. Liebmann.

Future Curative Biotechnology Press Releases and Updates

Interested investors and shareholders can be notified of future press releases and industry updates by e-mailing ir@curativebiotech.com

About Curative Biotechnology, Inc.

Curative Biotechnology, Inc. (Curative Biotech) is a development stage biomedical company focused on novel therapies for rare diseases. The Company is identifying, acquiring, and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. Curative Biotech currently has ongoing programs in three (3) different therapeutic areas: degenerative eye disease, infectious disease, and neuro oncology. The Company is now concentrating its energy and resources on its degenerative eye disease platform, based on a worldwide exclusive license from the National Eye Institute (NEI) at the National Institutes of Health (NIH). The first therapeutic in development on this platform is a Metformin Reformulation targeting the treatment of intermediate and late-stage Age-Related Macular Degeneration (AMD) disease with the goal of being in the clinic in 2024 for a first in human trial of its metformin-based eye drop. The trial will be conducted under a Cooperative Research and Development Agreement (CRADA) with the NEI.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. CUBT is not yet generating revenues. Although forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subjected to known, unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements, including but not limited our ability to generate sufficient market acceptance for our products and services, our ability to generate sufficient operating cash flow, and general economic conditions. Readers are urged to carefully review and consider the various disclosures made by us in our reports filed with OTC Markets from time to time which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Contact:

Steve Chizzik
Investor Relations
Curative Biotech (CUBT)
201-454-5845
ir@curativebiotech.com